This week, we cover key updates from the American Association for Cancer Research (AACR) 2024 Annual Meeting, held in San Diego, CA. Hear from Scott Koptez, The University of Texas MD Anderson Cancer Center, Houston, TX, Rebecca Porter, Dana-Farber Cancer Institute, Boston, MA, Pasi Janne, Dana-Farber Cancer Institute, Boston, MA, and Elizabeth Swisher, Fred Hutchinson Cancer Center, Seattle, CA, as they discuss takeaways from the meeting. The post Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE appeared first on VJOncology ..read more

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat head and neck cancer. This week we will be joined by Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Ari Rosenberg, MD, University of Chicago, Chicago, IL and Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA. We will hear about the results of the SAKK 11/16 trial (NCT02999646) of the MVX-ONCO-1 vaccine, a Phase I dose expansion t ..read more

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands. We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906 ..read more

In this week’s podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening and treatment, drawn from highlights of the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. One key focus was the rapid evolution of non-invasive blood-based tests for colorectal cancer screening, as discussed by Aasma Shauka from New York University. Further, Theodore R. Levin from Kaiser Permanente shared the effectiveness of stool-based testing in achieving high adherence rates for colorectal cancer screening. Meanwhile, Seb ..read more

This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker. Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurren ..read more

Invasive lobular carcinoma (ILC) poses unique challenges in breast cancer management. Its subtle presentation and distinct biological behavior demand a nuanced approach from healthcare professionals. In this podcast, we delve into the epidemiology, pathology, diagnostic methods, treatment modalities, and emerging research surrounding ILC. By comprehensively understanding this subtype, healthcare professionals can optimize patient care and ultimately improve patient outcomes. In this enlightening podcast from VJ Oncology, join our distinguished guests, Jason Aboudi Mouabbi, MD, The University o ..read more

In this podcast, we will discuss key insights from the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. Topics include updates in the KEYNOTE-811, MATTERHORN, and CheckMate 649 trials, as well as the use of circulating free DNA analysis in esophagogastric cancer and the evolving landscape of treatment of HER2-positve metastatic gastric cancer. Additionally, hear on a pilot PET study using the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging in advanced esophagogastric cancer and a retrospective investigation into the concordance between three PD-L1 scoring m ..read more

In this podcast, we will discuss key insights from the 2024 ASCO Genitourinary (GU) Cancers Symposium held in San Francisco, CA. Topics include updates in the AMBASSADOR, CONTACT-2, and CLEAR trials, as well as why BCG-unresponsive patients with non-muscle invasive bladder cancer refuse cystectomy and the emerging role transperineal prostate biopsies. Tune in to hear perspectives from experts such as Andrea Apolo (National Institutes of Health, Bethesda, MD), Kim Chi (BC Cancer Vancouver Centre, Vancouver, Canada), Viktor Grünwald (University Hospital Essen, Essen, Germany), Joseph Jacob (Upst ..read more

In this podcast, we will discuss key insights from the 2024 ASCO Genitourinary (GU) Cancers Symposium held in San Francisco, CA. Topics include updates in the AMBASSADOR, CONTACT-2, and CLEAR trials, as well as why BCG-unresponsive patients with non-muscle invasive bladder cancer refuse cystectomy and the emerging role transperineal prostate biopsies. Tune in to hear perspectives from experts such as Andrea Apolo (National Institutes of Health, Bethesda, MD), Kim Chi (BC Cancer Vancouver Centre, Vancouver, Canada), Viktor Grünwald (University Hospital Essen, Essen, Germany), Joseph Jacob (Upst ..read more

In this podcast, we’ll be covering highlights from the PROCSA/BLADDR 2023 Meeting, which took place in Valencia, Spain, such as the evolution of targeted therapies and novel biomarker driven studies in prostate cancer, as well as trimodal therapy for non-muscle invasive bladder cancer. Hear from Rob Jones (The University of Glasgow, Glasgow, UK), Bertrand Tombal (Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium), Daniele Raggi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Bram De Laere (Ghent University, Ghent, Belgium), Paul Sargos (Institut Bergonié, Bo ..read more